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Abstract 
 
Ionizing procedures provide essential life-saving information, but great care must be 
taken regarding their possible long-term health consequences. The biological and 
clinical burdens of medical radiation represents a worrisome social and medical 
problem. DNA damage is the main initiating event by which radiation may results in 
cancer development. Thus considerable efforts should be made to mitigate radiation-
induced cell damage. Because radiation induced cellular damage is attributed primarily 
to the harmful effects of free radicals, the efficacy of non-toxic radioprotectors with 
radical scavenging properties should be investigated in the clinical setting. These 
agents may inhibit or reduce free radical toxicity, thus offering protection against 
radiation. N-acetylcysteine (NAC) is considered a promising radio-protector for its 
antioxidant and anticarcinogenic properties and could be able to  inhibit or reduce free 
radical toxicity, thus offering protection against radiation. 
Moreover, recent evidences have recognized that genetic factors influence the risk of 
radiation-induced effects and the Seventh National Academy of Science report on 
Biological Effects of Ionizing Radiation (BEIR VII) included the identification of genes 
conferring predisposition to radiation-induced health effects as a top research need. 
Genetic polymorphisms in the detoxification and DNA repair genes are specifically 
proposed as candidates for genetic predisposition to radiation-induced biological 
damage. The identification and characterization of genes that enhance prediction of 
disease risk and improve prevention, treatment, and quality of care remain important 
goals in the modern imaging practice. Specifically, it is anticipated that the use of 
genetic markers may serve as the basis for personalized radiotherapy in which cancer 
management is formulated so that it optimizes the treatment plan for each patient 
based on their genetic background (radiogenomics).  
In order to improve this knowledge, the primary aims of the project were: 
- Aim 1: to evaluate the ability of NAC in conferring protection against radiation 
induced chromosomal DNA damage. 
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- Aim 2: to assess the value of functional polymorphisms of genes involved in DNA 
damage repair and oxidative stress response as predictive factors for the 
occurrence of acute skin reactions. 
To reach aim 1, 65 patients undergoing invasive cardiovascular procedures received 
the standard hydration protocol consisting of intravenous isotonic saline for 12 h after 
catheterization (Group I) while 30 patients received a clinically driven double 
intravenous dose of NAC for 1 hour before and a standard dose for 12 hours following 
catheterization (Group II). Micronucleus assay (MN) was performed as biomarker of 
chromosomal damage and intermediate endpoint in carcinogenesis. MN frequency 
evaluated before, 2 and 24 hours after the radiation exposure showed a significant 
increase of 24.1% at 2 hours and of 21.4 % at 24 hours in the Group I (p=0.03), while 
the non-significant increase of MN was 13.1% at 2 hours and 8.7% at 24 hours in Group 
II (p=0.4). These results suggested that NAC may be an effective promising, well-
tolerated antioxidant approach easily usable in the clinical practice to offer protection 
against DNA damage induced by ionizing radiation exposure during cardiac 
catheterization procedures.  
To reach aim 2, skin toxicity was scored according to Radiation Therapy Oncology 
Group (RTOG) criteria in 59 breast cancer patients undergoing radiation therapy after 
conserving surgery. Single nucleotide polymorphisms (SNPs) in XRCC3 (Thr241Met), 
XRCC1 (Arg399Gln, and Arg194Trp) and in GSTT1 and GSTM1 were determined by PCR-
RFPL analysis. According to RTOG criteria, grade 1 and 2 acute skin reactivity was 
observed in 24 (41%) of the 59 participants. Univariate analysis indicated that XRCC3 
241Met variant (OR: 2.5 95% CI: 1.0-7.3, p=0.05) and  GSTM1 null genotype (OR: 3.5 
95% CI:1.2-10.4 p=0.02) as well as BMI  (OR: 3.6 CI: 1.2-11, p=0.02) were associated 
with the risk of acute skin radiosensitivity. The logistic multivariate analysis confirmed 
that the two genetic variants increased the individual susceptibility to acute skin 
reaction. Our findings suggest that the presence of SNPs involved in DNA repair and 
oxidative stress may in part explain the individual response to acute skin toxicity in 
patients undergoing partial breast irradiation after conserving surgery. The association 
analysis between clinical characteristics and genotype with the acute radiation skin 
toxicity in breast cancer patients suggests that approaches based on (multiple) genetic 
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markers and clinical characteristics have the potential to predict normal tissue 
radiosensitivity.  
Although our findings are to be carefully assessed with further large, randomized 
studies, taken together have outmost clinical relevance since add important 
information to reach a personalized measure of radiation risk in order to implement 
tailored preventive and chemopreventive strategies.  
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1 Introduction 
 
1.1 Radiation exposure from medical imaging procedures 
Ionizing radiation is daily used in diagnostic radiology and nuclear medicine to better 
visualize organ and/or vessel anatomy to have physiological information that help the 
clinicians in the treatment of disease. The diagnostic information can provide a better 
understanding of a patient disease, prognosis, treatment response, or to guide 
therapy. Medical imaging is an essential tool in clinical filed as confirmed by its 
increased use in the United States in the last ten years: from 26 million in 1998 to 
more than 70 million in 2008. A recent report on medical radiation exposures in the US 
population shows that the pro-capite collective dose of radiation received from clinical 
imaging has increased by greater than 700% between 1980 and 2006 [Mettler FA, 
2008] and cardiac imaging has contributed greatly to this warming [Bedetti G, 2008; 
Ait-Ali L, 2010; Kaul P, 2010]. Despite many clinical advantages, ionizing radiation is 
recognized as a proven human carcinogen. The increasing exposure to medical imaging 
might result in a raising incidence of radiation-related cancer[Brenner DJ, 2007]. 
Accordingly, medical imaging has been identified as one of the major causes of 
environmental exposure to carcinogens [President’s Cancer Panel, 2010]. Exposure to 
ionizing radiation carries a carcinogenesis risk that is thought to be linear and 
cumulative. According to the “linear-no threshold” (LNT) model, no radiation doses - 
no matter how small - can be     considered completely safe [BEIR VII 2006; ICRP 2007, 
UNSCEAR 2008]. The National Research Council Committee on the Biological Effects of 
Ionizing Radiation (BEIR VII) of the National Academy of Sciences have confirmed the 
LNT model in a recent updated report on the health risk of exposure to ionizing 
radiation [BEIR VII 2006]. This update considers the evidence obtained in 
epidemiological studies of exposed populations that include atomic bomb survivors, 
patients exposed to radiation from diagnostic and therapeutic medical studies, as well 
as studies of occupational and environmental exposures [BEIR VII, 2006].  
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In the last years, many studies have provided a consistent evidence that several 
genetic, environmental and dietary factors can affect the variability of damage 
observed at any given level of radiation. Thus current research is target in shifting 
epidemiological evidence towards personalized measure of radiation risk in order to 
implement tailored preventive and chemopreventive strategies. 
 
 
1.2 Ionizing radiation in cardiac catheterization procedures  
 
Over the last 20 years, the number of interventional cardiovascular procedures has 
increased rapidly. In Europe, arteriography and interventions were 350,000 in 1993 
and > 1 million in 2001 [Togni M, 2004]. On average, a left ventriculography and 
coronary angiography correspond to a patient radiation exposure of about 300 chest x-
rays; and a percutaneous coronary intervention or a cardiac radiofrequency ablation to 
750 chest x-rays (range: 350-2350) [Gerber RT, 2009].  
The attributable cancer risk of getting cancer from a 15 mSv exposure is 1 in 750 for an 
adult male and 1 in 500 for a woman Children are especially vulnerable. The same dose 
confers an extra-risk for a 1-year old infant 10-15 times greater than a 50 year old 
adult, and female infants have almost double the risk than that of male infants. The 
typical effective doses for common cardiologic testing are reported in Table 1. 
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Table 1. Typical effective doses from diagnostic medical exposure 
 Diagnostic procedure 
Typical effective 
dose (mSv) 
Equivalent 
number of 
chest x-rays 
Approximative 
equivalent 
period of natural 
background 
radiation (years) 
ADULT 
Diagnostic invasive 
coronary angiogram 
7 (2-16) 350 2.9 
 
Percutaneous 
coronary intervention 
15 (7-57) 750 6.2 
 
Radiofrequency 
ablation 
15 (7-57) 750 6.2 
 Mitral valvuloplasty 29 1450 12.1 
 Aortic valvuloplasty 39 1950 16.2 
 
Head and/or neck 
angiography 
5 (1-20) 250 2.1 
 
Thoracic angiography 
of pulmonary artery or 
aorta 
5 (4-9) 250 2.1 
 
Abdominal 
angiography or 
aortography 
12 (4-48) 600 5 
 
Pelvic vein 
embolization 
60 (44-78) 3000 25 
 
Transjugular 
intrahepatic 
portosystemic shunt 
placement 
70 (20-180) 3500 29.1 
     
PEDIATRIC Diagnostic cardiac cath 6.0 (0.6-23.2) 300 2.5 
 ASD 2.8 (1.8-7.4) 140 1.1 
 
Patent ductus 
arterovenous 
occlusion 
7.6 (2.1-37) 380 3.1 
 Balloon dilation 8.1 (2.9-2.0) 405 3.3 
 
In adult cardiology patient, interventional cardiology procedures account for 12% of 
examinations, and 48% of the total collective dose [Bedetti G, 2008]. In children with 
congenital heart disease, invasive cardiology (with diagnostic and interventional 
catheterization) accounts for 6% of all radiological examinations and 84% of the 
collective dose [Ait-Ali L, 2010]. Also, the number of professionally exposed subjects in 
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the catheterization laboratory continues to rise. According to 2008 UNSCEAR 
estimates, the number of occupationally exposed workers totals 22.8 million (plus 
military personnel), and 7.35 million of these are medical workers [UNSCEAR, 2008]. 
Among medical workers, interventional cardiologists have by far the highest exposure, 
corresponding to the dose equivalent of 200 to 300 chest x-rays per head per year, 
two-to-three times higher than radiologists or nuclear physicians, with a corresponding 
levels of long-term lifetime attributable cancer risks in the range of 1 extra-cancer in 
50- 1 in 200 [Venneri L, 2009]. These estimates have been also recently corroborated 
by direct assessment of biological damage resulting from ionizing catheterization 
procedures in both patients and personnel operating in catheterization laboratory. 
These studies have shown that interventional cardiology procedures can damage the 
DNA of the cell to be detectable-acutely and in the long-term as increased 
chromosomal DNA damage in circulating lymphocytes that represent an intermediate 
endpoint of cancer [Hagmar L, 1998; Bonassi S, 2007]. Indeed, the lifetime exposure of 
a young adolescent with congenital heart disease in the range of 20 mSv is associated 
with a dramatically 200% increased frequency of chromosomal DNA damage when 
compared to age- and sex-matched control subjects [Andreassi, 2006]. Furthermore, 
contemporary interventional cardiologists have an increased rate of chromosomal 
damage when compared to clinical cardiologists [Andreassi, 2005]. Interestingly, 
radiation-associated chromosomal damage in interventional cardiologists is associated 
to the presence of specific genetic polymorphisms suggesting that the risk estimates at 
the population level can be highly inaccurate at the individual level [Andreassi, 2009] 
 
 
1.3 Radiation therapy for the treatment of breast cancer  
 
Radiation therapy is one of the most important modalities for treating various types of 
localized cancer, and can be used as a form of palliative therapy for symptoms once a 
patient develops metastatic disease. Breast cancer is the most common form of cancer 
in women especially in industrialized areas [IARC, 2000]. In Europe, it represents 30% 
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of all incident tumors in females with rates ranging from about 40/100000 in Lithuania 
and Poland, to 75/100000 in Norway, and to over 90/100000 in the Netherlands and 
some Italian areas [Ferlay J, 2007]. Overall, the annual breast cancer incidence has 
been increasing worldwide during the last century, but a declining trend in tumor 
incidence was observed since the year 2000 among women older than 45–50 years in 
the United States and some European countries. This decreasing trend may be 
ascribed to the decreased use of hormone replacement therapy [Merlo DF, 2012]. 
Therefore, the early detection and immediate treatment of breast cancer are two main 
factors influencing the prognosis of the disease. Surgery, chemotherapy and 
radiotherapy are the three mainstays in cancer treatment. 
Surgery is a very effective form of treatment, because solid tumors can be resected in 
their entirety together with all adjacent tissue into which the tumor may have spread. 
For a long time, radical mastectomy has been used to treat women with breast cancer. 
Nowadays, a segmental mastectomy or breast-conserving therapy is used when 
possible to maintain a normal breast appearance after the surgery [Stephens FO, 
2009].  
Chemotherapy is the treatment of cancer with cytotoxic drugs affecting cell division. 
These drugs are generally classified according to their mechanism of action, including 
antimetabolites (e.g. 5-fluoruracil), DNA damaging agents (e.g. cyclophosphamide), 
mitosis inhibitors (e.g. taxol) and cancer cell enzyme in-activators (e.g. tyrosine-kinase 
inhibitors). All these drugs, however, have side effects [Stephens FO, 2009].  
The third hallmark of cancer treatment is radiation therapy, which uses X-rays to 
destroy the tumor. Around 50% of patients are treated with radiation therapy (World 
Cancer Report [Stewart BW, 2003]), alone or in combination with surgery and 
chemotherapy. Radiotherapy after breast-conserving surgery is now widely accepted 
as the standard of care for patients with early breast cancer. This technique reduces 
the risk of loco-regional recurrence of cancer by approximately 70%, and has been 
shown to be as effective as radical mastectomy [Fisher B, 2002]. If on the hand 
radiation therapy destroys the cancer cells remained after surgery, on the other hand 
causes radiation-induced side-effects in the surrounding normal healthy tissues 
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[Barnett GC, 2009]. Breast-conserving surgery instead of radical mastectomy 
represents a good strategy for the reduction of normal tissue toxicity. While today the 
majority of patients well tolerates standard radiation therapy, clinicians still observe a 
substantial amount of patients (up to 10%) who suffer from adverse effects arising 
from the intrinsic sensitivity of healthy tissues [Bentzen SM, 2003]. Normal tissue 
reactions are of clinical importance since affect the patient quality of life.  
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2 Early biological effects of ionizing radiation 
 
The biological effects of ionizing radiation may be manifested as clinical symptoms and 
can be classified into two categories: deterministic and stochastic effects. 
Deterministic effects, such as erythema or cataracts, are mainly based on extensive cell 
death. They are most often seen in cases of high doses of radiation delivered over a 
short period of time (i.e. in the case of acute exposure in radiation accidents or 
radiation therapy) and they have a threshold dose below which the biological response 
is not observed. The severity of deterministic effects increases sharply with increasing 
dose. A stochastic effect is a probabilistic event and there is a known threshold dose. 
Indeed, damage to the DNA is considered the early event in radiation-induced 
stochastic effects. Damage to the DNA, which carries the genetic information in the 
chromosomes of the cell nucleus, is considered to be the main initiating event by 
which radiation damage to cells results in the development of cancer and hereditary 
disease in the exposed subjects [Andreassi MG, 2004].  
 
 
2.1 Radiation induced DNA damage 
 
The damage to DNA can cause single-strand breaks, double-strand breaks (DSBs) and 
cross-links. A single-strand break (SSB) is formed when the phosphodiester bond 
between the sugars on the DNA strand is broken. If this occurs on both strands, within 
a distance of 10–20 base pairs, neither the hydrogen bonds between base pairs nor the 
chromatin structure will be strong enough to keep the strands together, giving rise to a 
double-strand breaks [Magnander K, 2012]. This damage can be repaired on a minute 
time-scale after the damage has occurred by the activation of DNA repair genes. 
Radiation-induced SSB are usually readily repaired using the opposite DNA strand as a 
template. Radiation-induced DSBs are the most biologically important DNA lesions, as 
they are usually accompanied by extensive base damage, a phenomenon termed 
“locally multiply damaged site(s)‟. The capacity of normal cells to repair damage of 
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DNA is genetically determined and varies between individuals. More than 150 
polymorphic genes have been described in DNA repair pathways. This genetic variation 
is linked with the differing sensitivities of individuals to radiation damage [Feinendegen 
LE, 2007; Franco N, 2005].  
With a delay of several hours, the damaged cells with unrepaired or mis-repaired DNA 
damage can be removed by apoptosis, necrosis and appropriate immune responses 
[Martin LM, 2010]. However, some cells may ‘escape’ from these protective 
mechanisms and genomic instability and  oncogenic transformation with potential 
cancer development  may occur [Sedelnikova OA, 2010; Asaithamby A, 2011].  
 
 
2.1.1 Direct and indirect DNA damage 
 
Radiation damage to DNA can be ascribed to both direct and indirect mechanism (Fig 
1). Direct damage occurs as a result of the interaction of radiation energy with DNA. 
The indirect DNA damage of ionizing radiation is due to the production of free radicals 
such as superoxide anion (O2
-), hydrogen peroxide (H2O2) and hydroxyl radical (OH
-), 
which are generated during radiolysis of water. These radicals are effective oxidants 
able to break chemical bonds and initiating DNA damage, within the nano- to 
microsecond timeframe. If direct and indirect damages following radiation exposure 
are not repaired, the cell structure and function will be affected [Gaigeot MP, 2010]. 
Endogenous or exogenous levels of radiation-protective agents (see section 2.1.3) are 
determinants of the cellular scavenging capacity [Karin M, 2012].  
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Figure 1. Effect of radiation: chain of the cellular events occurring in the cell/ tissue 
after ionizing radiation exposure [From Gaigeot MP, 2010] 
 
 
2.1.2 The micronucleus assay in peripheral lymphocytes as a 
biomarker of DNA damage 
 
Cytogenetic alterations in cultured peripheral blood lymphocytes, such as 
chromosomal aberrations (CAs), sister chromatid exchanges (SCEs), and micronuclei 
(MN), have been applied as biomarkers of genotoxic exposure and early effects of 
genotoxic carcinogens for many years [Albertini RJ, 2001; Norppa H, 2004]. The 
rationale of using these assays derives from the evidence that most established human 
carcinogens are genotoxic in short-term tests and capable of inducing chromosomal 
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damage [Norppa H, 2004]. The relevance of the increased frequency of cytogenetic 
alterations as a cancer risk biomarker is further supported by epidemiological studies 
suggesting that a high frequency of CAs is predictive of an increased risk of cancer 
[Hagmar L, 1998; Bonassi S, 2000]. CAs are structural aberrations comprising of 
chromosome-type and chromatid-type breaks and rearrangements [Norppa H, 2004].  
SCEs are interchanges of DNA replication products between sister chromatids at 
apparently homologous loci, suggested to represent homologous recombination repair 
of DNA double strand breaks [Johnson RD, 2000]. The two basic phenomena leading to 
the formation of MN in mitotic cells are chromosome breakage and dysfunction of the 
mitotic apparatus. MN are small additional nuclei originating from chromosomal 
fragments or whole chromosomes that lag behind in anaphase (Fig.2) [Falck GC, 2002]. 
These fragments do not efficiently integrate in any of the daughter nuclei because they 
are incapable of attaching to the spindle fibers and are left behind during mitosis. 
During telophase, they are enclosed by the nuclear envelope and arise as micronuclei 
in the next cell cycle. If two broken chromosome ends are mis-repaired and fuse with 
each other, a CAs can be formed. Dicentric chromosomes can also be formed by the 
fusion of two unprotected ends resulting from telomeric dysfunction [Shay JW, 2005]. 
The two centromeres of the dicentric chromatids can be pulled to opposite poles 
during the next anaphase, forming a chromosomal bridge that is frequently resolved 
by breakage. This breakage may result in the formation of acentric fragments that, at 
the end of mitosis, arise as micronuclei [Hoffelder DR, 2004] or as nuclear blebs, which 
are micronucleus-like bodies physically connected to the nucleus by a chromatinic 
filament [Pampalona Ja, 2010; Pampalona Jb, 2010]. The broken bridge often 
constitutes a source of chromosomal instability, as the resulting unprotected 
chromosomal ends are susceptible to suffering further reorganization [Terradas M, 
2012]. Alternatively, micronuclei can contain a whole chromosome arising from 
anaphase loss. This loss is a consequence of defects during the mitotic spindle 
assembly, misregulation of the spindle assembly checkpoint or the presence of 
supernumerary centrosomes [Fenech M, 2011b]. It has also been shown that 
micronuclei can contain whole chromatids derived from the merotelic attachment of 
chromosomes to the mitotic spindle. In this sense, when a single kinetochore is 
connected to microtubule bundles coming from both poles, the affected chromatid 
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lags behind from the bulk of chromosomes and, at the end of mitosis, is enclosed into 
a micronucleus [Cimini D, 2002].  
 
Figure 2. Micronuclei and nucleoplasmic bridge formation in cells undergoing nuclear 
division 
 
In comparison with chromosomal aberrations (CA), the scoring of MN is simpler, 
requires shorter training and is less time consuming. In principle, the MN assay can be 
expected to be more sensitive than the CA assay, because of the increased statistical 
power brought about by the fact that the number of cells analyzed can easily be 
increased to thousands when only a hundred or a few hundred cells are usually scored 
for CA. 
MNs, usually detected in lymphocytes by the cytokinesis-block MN assay [Fenech M, 
1985] are the most frequently used chromosomal biomarker in human lymphocytes in 
order to study genotoxicity and cytotoxicity in vitro [Fenech J, 2007]. The use of the 
MN assay in peripheral lymphocytes is also employed as a biological dosimeter in order 
to evaluate in vivo ionizing radiation exposure [Vral A, 2011]. According to the different 
origin of micronuclei, their presence in cells is not only an indicator of mutagenic agent 
exposures but also an indicator of ongoing chromosome instability. Most importantly, 
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Bonassi et al. provided evidence that high micronucleus frequencies in peripheral 
blood lymphocytes of healthy individuals are predictive of higher cancer risks, 
suggesting that increased micronuclei formation is associated with early events in 
carcinogenesis in non exposed humans [Bonassi S, 2011; Bonassi S, 2007]. Recently,  
Ait-Ali et al. have shown an increase of micronucleus frequencies in peripheral blood 
lymphocytes of exposed children few hours after the end of the catheterization 
procedure [Ait-Ali L, 2010]. Significant somatic DNA damage, measured by an acute 
increase in micronuclei in circulating lymphocytes has been also demonstrated in 
patients undergoing invasive cardiovascular procedures and medical staff [Andreassi 
MG, 2005; Andreassi MG, 2007].  
 
 
2.1.3 Radiation-protective agents in the reduction of radiation 
damage 
 
The term ‘radiation-protective agent’ refers to any agent that protects against 
radiation-induced damage, whether administered before, during, or after irradiation 
[Stone HB, 2004]. Radioprotectants, radiation mitigators (or mitigants), and 
therapeutic agents are the three main classes of ‘radiation-protective agent’ as defined 
in Table 1. Radioprotectants are administered before radiation exposure to prevent 
damage; mitigators are administered during or after radiation exposure with the aim 
of preventing or reducing the action of radiation on tissues before the appearance of 
symptoms. Finally, therapeutic agents are administered after radiation exposure to 
treat or facilitate recovery from various aspects of the acute radiation syndrome and 
delayed effects of radiation exposure [Dumont F, 2010].  
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Table 2. Main classes of radiation countermeasure agents [From Dumont F et al, 
2010] 
 
 
Thousands of compounds have been tested for radio-protective effects but most of 
them have only been tested on cell cultures and rodents using lethality as an end point 
[Liu Y, 2007]. An extensive review has been conducted by Weiss and Landauer [Weiss 
JF, 2009]. The main types of antioxidants are sulfhydryl compounds, polyphenols, 
superoxide dismutase, and vitamin E analogs [Coleman CN, 2003]. The best known 
class of them are the sulfhydryl compounds. The radioprotective properties of such 
compounds, including cysteine and cysteamine, were investigated as early as the late 
1940s. These compounds rely on a potential sulfhydryl group at the end of the 
molecule for free-radical scavenging and also hydrogen atom donation to facilitate 
direct chemical repair at sites of DNA damage.  
N-Acetylcysteine (NAC) is a natural compound found in several vegetables that is 
considered to be the most “natural” of the thiol protectors and is approved for human 
use for various purposes [Weiss JF, 2003]. NAC, an aminothiol and synthetic precursor 
of intracellular cysteine and GSH, has been used as a mucolytic agent. In addition, it 
has been shown to prevent radiation-induced DNA damage [Mansour HH, 2008]. 
Kuefner et al. have shown that the administration of a radiation-protective oral agent 
containing a mixture of antioxidants such as α−tocopheryl succinate, N-acetylcysteine,  
glutathione elevating compounds, can reduce DNA damage by 23% after CT 
examinations [Kuefner MA, 2012]. Recently radioprotective effects of NAC have been 
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demonstrated on radiation toxicity in intestinal [Sridharan S, 2002] and hepatic tissue 
[Mansour H, 2008]. Several clinical studies also demonstrated the efficacy of NAC in 
the prevention of contrast-induced nephropathy in unselected populations undergoing 
procedures involving intravascular contrast administration [Isenbarger W, 2003; Birck 
R, 2003;  IAEA, 2001; Wu MY, 2013]. The evidence from in vivo studies suggests that 
NAC is capable of replenishing intracellular GSH by reducing extracellular cystine to 
cysteine [Issels RD, 1988], or by supplying sulfhydryl groups that can stimulate GSH 
synthesis and enhance glutathione-S-transferase activity [De Flora S, 1985]. NAC is a 
potent free radical scavenger as a consequence of its nucleophilic reactions with 
reactive oxygen species (ROS) [De Flora S, 2001]. Thus, NAC treatment may be 
beneficial for conditions of free radical formations during oxidative stress [Reliene R, 
2004; Mansour HH, 2008].  
 
 
2.2 Radiation induced tissue toxicity 
 
A substantial amount of cell killing, sufficient to result in detectable tissue reactions, 
may be the direct consequence of high dose radiations. This cellular response may 
occur early (days) or late (months to years) after irradiation, depending on the tissue. 
The manifestations of tissue injury vary from one tissue to another depending on 
cellular composition, proliferation rate and mechanisms of response to radiation. 
Examples include cataracts of the lens, cell depletion in the bone marrow causing 
hematological deficiencies, non-malignant damage to the skin (i.e. skin-toxicity during 
radiation therapy) [Annals of the ICRP, 2011].  
Radiation-induced skin toxicity is a prominent clinical problem affecting the majority of 
breast cancer patients receiving breast radiation therapy (RT) after conservative 
surgery. Acute and chronic toxicities have been assessed in patients treated with 
adjuvant breast RT, including skin (30-40%) and heart toxicity (1.5%) [Clarke M, 2005;  
Darby SC, 2005]. Today most patients tolerate well standard RT but RT-induced skin 
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toxicity is still a relevant clinical problem affecting a substantial amount of breast 
cancer patients receiving adjuvant RT and can lead to temporary or permanent 
cessation of treatment [Chen MF, 2010].   
 
2.2.1 Non-neoplastic-tissue reaction after Radiation Therapy (RT) 
 
Non-neoplastic or normal tissue toxicity to RT is commonly classified according to the 
time taken to exhibit clinical injury into early and late effects. Early tissue reactions 
(hours to a few weeks after irradiation) may be of an inflammatory nature, occurring 
as a result of cell permeability changes and release of inflammatory mediators. 
Subsequent reactions are often a consequence of cell loss e.g. mucositis and 
desquamation in epithelial tissues, although non-cytotoxic effects on tissues also 
contribute to these early reactions. Early reactions include erythema, epilation and 
desquamation. 
Late tissue reactions (months to years after irradiation) are called “generic” if they 
occur as a result of injury directly in the target tissue e.g. vascular occlusions leading to 
deep tissue necrosis after protracted irradiations, or “consequential” if they occur as a 
result of severe early reactions, e.g. dermal necrosis as a result of extensive epidermal 
denudation or chronic infection, and intestinal strictures caused by severe mucosal 
ulceration [Dorr W, 2001]. Late reactions include dermal erythematous reactions, 
atrophy, induration, telangiectasia, necrosis and fibrosis. However, it is important to 
realize that early and late tissue reactions are not mutually exclusive and may often 
coexist. Skin reaction during RT is the most frequent normal tissue side-effects and can 
affect the therapeutic program and worsen the quality of life of patients [Bentzen SM, 
2003].  
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2.2.2 Inter-individual variations in the development of tissue 
toxicity  
 
There has been intense interest in the phenomenon of inter-individual variation in 
normal tissue toxicity in response to RT treatment. Next to the issue of normal tissue 
toxicity in the RT treatment of cancer patients, large inter-individual variations in the 
rate and severity of the development of these reactions is seen. This accounts for 
acute reactions as well as for late reactions. The parameters influencing the individual 
radiosensitivity can be subdivided into: 
• Therapy-related factors (total dose, dose per fraction and volume irradiated, 
irradiation site, dose inhomogeneity and use of concomitant chemotherapy). 
• Patient characteristics (age, smoke status, hemoglobin level and co-morbid 
conditions such as diabetes, hypertension, vascular diseases).  
• Genetic background (genetic variants, most often, single nucleotide polymorphism in 
DNA repair and detoxification genes may influence inter-individual variation in normal 
tissue toxicity). 
Therapy related factors such as the total tumor dose, the dose per fraction, and the 
dose-volume on the healthy tissues have an impact on the incidence and severity of 
acute as well as chronic normal tissue toxicities [Stone HB, 2003]. Additional treatment 
modalities like chemotherapy and surgery cause further traumas that can significantly 
aggravate the radiation responses [Joiner M, 2009; Stone HB, 2003; Azria D, 2008].  
The dose-effect relationship is stronger for the late responsive tissues compared to the 
acute responding tissues. Treatment regimes that result in a decrease in the total 
tumor dose therefore could reduce the incidence and severity of late adverse effects 
[Azria D, 2008]. The dose per fraction generally influences the severity of both the 
acute and late effects, although late responding tissues are the most sensitive to 
changes in the dose per fraction [Stone HB, 2003 ]. Late responding tissues therefore 
show a greater ability to recover during fractionated exposure than early responding 
tissues. Hyperfractionation regimes (lower dose per fraction, multiple fractions a day) 
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could lower the incidence of late toxicities without a decrease in total tumor dose and 
therefore without affecting the cure rates. This is because the shoulder (large for late 
responding tissues) of the cell survival curve at low radiation doses is repeated when 
the dose is split in multiple fractions [Willers H, 2006]. The difference in fractionation 
sensitivity of early- and late responding tissues is described using the α/β ratio. The 
α−component is responsible for the linear component of the survival curve 
(unrepairable damage). The downward bending component is caused by the -
component (‘shoulder’: repair of sublethal damage). The α/β ratio represents the dose 
for which α and β equally contribute to the cell damage [Bomford CK, 1993].  
The risk of adverse effects after RT is also influenced by general condition and habits of 
the patients. Age, nutritional status, medications, recent surgery in an irradiated site 
and co-morbidities, especially those affecting normal vascular function like diabetes, 
connective tissue disease and arterial hypertension are widely considered to affect the 
expression of radiation-induced morbidity [Hölscher T, 2006]. Lifestyle behaviors such 
as smoking tobacco, consuming alcohol, eating spicy can intensify the response to RT 
as well [Joiner M, 2009]. Patients who continue to smoke during their therapy for head 
and neck cancer show a significant increase in acute skin reactions [Porock D, 2004]. 
Treatment- and patient-related parameters can explain only a part of variability 
existing among individuals. The hypothesis that patient radiosensitivity can be affected 
by the genetic alterations in some genes originates from the studies of patients with 
certain rare genetic syndromes such as ataxia telangiectasia, Nijmegen breakage 
syndrome, Fanconi's anaemia and Bloom's syndrome. Although these syndromes are 
rare and not representative for the general unselected cancer patients, they do act as 
a proof of principle that genetic factors can influence an individuals’ sensitivity to 
ionizing radiation. Acute side effects (erythema and desquamation of skin) occurring 
during or shortly after radio-treatment are normally checked by clinicians since they 
are particularly interested in predicting the normal tissue reactions of patients before 
radiotherapy starting in order to personalize the therapy and optimize the results. 
During last decade mutations in repair genes have been detected in extremely 
radiosensitive cancer patients, not suffering from any known syndrome [Rogers PB, 
2000]. Normal-tissue toxicity in breast cancer patients following RT after conserving 
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surgery correlate with several different genetic alterations [Suga T, 2007; Moullan N, 
2003]. Abnormal DNA repair and cell death regulation in such individuals may result in 
higher vulnerability to irradiation. Some of them also manifest chromosome instability 
that is associated with higher incidence of cancer [Bourguignon MH, 2005]. In vitro 
assays for the radiosensitivity of peripheral blood lymphocytes have suggested that 
breast cancer patients are more radiosensitive than healthy controls [Burrill W, 2000; 
Scott D, 1998].  
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3. Individual genotype and ionizing radiation susceptibility 
 
Mammalian cells have evolved distinct mechanisms to repair different types of DNA 
damage to maintain genomic integrity. Humans showing severely compromised repair 
capacity have increased mutation rates, genomic instability and an increased risk of 
cancer [Berwick M, 2000]. Healthy subjects can also differ in intrinsic capacity in 
repairing DNA damage [Setlow RB, 1983]. Single nucleotide polymorphisms (SNPs) in 
DNA repair gene can affect the individual susceptibility to radiation exposures. These 
SNPs significantly contribute to the increased amount of unrepaired DNA damage that 
in turn, results in a raised mutation frequency, genetic instability and acute skin 
toxicity [Chang-Claude J, 2005; Andreassen CN, 2005]. Nowadays,  radio-genomic, the 
research focused on the study of genetic variations to explain the inter-individual 
differences in response to therapeutic radiation exposure, is of increasing interest. The 
modulation of repair capacity by SNPs in genes responsible for DNA damage repair and 
detoxification enzymes might affect the individual sensitivity to radiation damage 
[Parliament MB, 2010]. As a consequence of radiation-induced DNA damage, the cells 
activate highly conserved mechanisms for the maintenance of genomic integrity and 
reparation of DNA lesions: 
• Base excision repair (BER) removes and corrects damaged bases and single 
strand breaks; 
• Nucleotide excision repair (NER) removes pyrimidine dimers and large chemical 
adducts; 
• Homologous Recombination Repair (HRR) and Non-Homologous End Joining 
(NHEJ) are employed to repair double strand breaks. 
Nuclear excision repair (NER) and base excision repair (BER) are activated after DNA 
single-strand breaks. In addition, to repair DNA double strand breaks (DSB) the cells 
can use two distinct pathways: non-homologous end joining (NHEJ) or homologous 
recombination (HR) repair systems. To minimize the harmful effects of radiation-
increased oxidative stress levels the cells have also evolved a variety of antioxidant 
enzymes, such as glutathione S-transferases, that play an important role in the 
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detoxification of ROS generated by radiation-induced oxidative stress. [Ambrosone CB, 
2001] 
 
 
3.1 DNA single-strand break repair genes  
 
Single-strand breaks (SSBs) in DNA are considered as transient promutagenic lesions, 
representing direct effects of damaging agents. They may also be related to 
apurinic/apyrimidinic sites (alkali-labile sites appearing as breaks) and also represent 
intermediates in cellular repair, since both Nucleotide Excision Repair (NER) and Base 
Excision Repair (BER) cut out the damage and replace it with undamaged nucleotides 
[Vodicka P, 2004]. 
NER and BER are two major cellular responses that correct DNA damage in mammalian 
cells. NER is one of the most versatile and important pathways by which mammalian 
cells remove a variety of DNA lesions, such as bulky chemical adducts, pyrimidine 
dimers and interstrand cross-links that distort the DNA helix. BER, however, is critically 
involved in the repair of single-strand breaks induced by reactive oxygen species, 
alkylation or ionizing radiation [Almeida KH, 2007]. Similar to BER, NER has four steps 
involving damage recognition and enzymatic denaturation, stabilization of damage, 
elimination of damaged nucleotides, gap-filling through DNA sysntesis and ligation 
(sealing) (Fig. 3). Defects in NER are associated with the inherited condition xeroderma 
pigmentosum, which is characterized by photosensitivity and a predisposition to 
cancer and neurological degeneration [Scriver CR, 1989]  
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Figure 3. Model for nucleotide excision repair pathway 
 
BER is composed of three main steps. (Fig 4) The first step is lesion recognition/strand 
scission by a lesion-specific glycosylase which catalyzes the hydrolysis of the N-
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glycosidic bond of the damaged deoxynucleoside. The damaged base is converted into 
an abasic site, which is a substrate for enzymes with endonucleolytic activity in a 
second step called Gap Tailoring. A poly (ADP-ribose) polymerase (PARP1) and a 
complex formed by DNA Ligase III with XRCC1, ligates the nucleotide to the DNA 
strand. The final step of repair is DNA synthesis and ligation [Schötz U, 2011]. 
Depending on the extent of replaced nucleotides, BER can be distinguished as a short 
patch (1 nucleotide) or a long patch (2–13 nucleotides) [Hegde ML, 2008].   
 
 
Figure 4. Base Excision Repair mechanism 
 
A number of proteins are involved in the BER process, of which poly (ADP-ribose) 
polymerase, X-ray repair cross-complementing group 1 (XRCC1) and 
apurinic/apyrimidinic endonuclease/redox effector-1 play important roles. XRCC1 is a 
major player in the base excision repair pathway. Cells defective in XRCC1 have been 
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shown to have an increased sensitivity to mitomycin, UV, and ionizing radiation 
[Thompson LH, 2000]. Common SNPs in XRCC1 gene, have been extensively studied for 
their influences in individual sensitivity to radiation exposure [Aka P, 2004;  Vodicka P, 
2004; Angelini S, 2005; Au WW, 2006; Cornetta T, 2006]. The XRCC1 gene is located on 
chromosome 19q13.2, and 33 kb in length. It consists of 17 exons, and encodes a 
protein of 633 amino acids which acts as a scaffold to coordinate BER proteins at the 
repair site. In order to correct DNA damage this protein interacts with poly (ADP-
ribose) polymerase (PARP1) at the site of damage. XRCC1 protein has two BRCA1 
carboxyl-terminal domains (BRCT1 and BRCT2), the BRCT1 domain binds protein PARP1 
to repair the damage. More than 300 SNPs in the XRCC1 gene have been validated in 
the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP), including Arg399Gln and 
Arg194Trp affected amino acid sequence and correlate with susceptibility to ionizing 
radiation damage. The polymorphism Arg399Gln is located close to BRCT1’s C-terminal 
boundary and codon 194 resides in a linker region connecting the domains BRCT1 and 
DNA polymerase. The functional consequence of both polymorphisms on the overall 
function of the protein is not clear yet. It was suggested that the mutation in codon 
399 and also the threonine (Thr) to Met polymorphism at codon 241 are non-
conservative changes in protein structure. These polymorphisms act by modifying the 
interactions between XRCC1 and other BER proteins involved in the repair pathway. 
Therefore, the reduced capacity in DNA damage restoration may result in an increased 
sensitivity to ionizing radiation damage [Chang-Claude J, 2005].  
 
 
3.2 DNA double-strand break repair pathways 
 
DNA double-strand breaks (DSBs) are considered to be the most relevant lesion for the 
deleterious effects of ionizing radiation exposure [Rothkamm K, 2003]. DSBs Repair 
involves two main mechanisms: DNA non-homologous end joining (NHEJ) and 
homologous recombination (HR).  
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In NHEJ, the DSB ends are blocked from 5’end resection and held in close proximity by 
the double-stranded DNA (dsDNA) end-binding protein complex. NHEJ promotes direct 
ligation of the DSB ends, but in an error-prone manner, frequently resulting in small 
insertions, deletions, substitutions at the break site, and translocations if DSBs from 
different parts of the genome are joined [Lieber MR, 2010]. In contrast to NHEJ, HR is 
largely error free and is initiated when the DSB is resected by nucleases and helicases, 
generating 3’single-stranded DNA (ssDNA) overhangs onto which the RAD51 
recombinase assembles as a nucleoprotein filament. This structure can invade 
homologous duplex DNA, which is used as a template for repair DNA synthesis. 
Although NHEJ is active throughout the cell cycle, HR is more prevalent after DNA 
replication, since an identical sister chromatid is available as a template for repair. HR 
requires a nucleolytic reaction that leads to formation of a single-stranded DNA 
(ssDNA) overhang at the break. A central role is played by the RAD51 complex, a small 
monomeric molecule which assembles into long helical polymers that wrap around the 
ssDNA tail at the break site [Johnson RD, 2001]. In addition to RAD51, a family of 
proteins known as the RAD51 paralogs and consisting of five proteins (RAD51B, 
RAD51C, RAD51D, XRCC2 and XRCC3), play an essential role in the DNA repair 
reactions through HR. The RAD51 paralogs act to transduce the DNA damage signal to 
effector kinases and to promote break repair [Suwaki N, 2011]. The XRCC3 gene is 
localized on chromosome 14q32.3, he encodes for a protein that directly interacts with 
and stabilizes Rad51 and is required for efficient repair of chromosome breaks 
[Brenneman MA, 2000]. The Thr241Met substitution is the most investigated 
polymorphism in XRCC3 due to a C18067T transition at exon 7. The functional 
consequence of XRCC3Thr241Met polymorphism on the overall function of the protein 
is yet not clear. It was suggested that conversion from one with a neutral hydrophilic 
hydroxyl group (Thr) to a hydrophobic one with a methyl sulphur group (Met) could 
represent a substantial change in protein characteristics which could affect protein 
structure and integrity. A large number of molecular epidemiologic studies have been 
preformed to evaluate the role of XRCC3 polymorphisms on the risk of various cancers 
[Manugueira M, 2006]. In addition, it has shown that XRCC3 Met241 variant influence 
radio sensitivity of human fibroblasts and that more risk allele of susceptible genes 
have a combined effect on cellular radiation response, suggesting that individuals with 
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multiple risk alleles could be more susceptible to radiation effects than those with 
fewer risk alleles [Alsbeih G, 2007].  
 
 
3.3 Glutathione-S-transferase genes  
 
Glutathione S-transferases (GSTs) are members of a multigene family of isoenzymes 
expressed in almost all living organisms. In both eukaryotes and prokaryotes they can 
be regarded as cellular housekeeping proteins, detoxifying many endogenous 
compounds as well as xenobiotics [Habig WH, 1974; Hayes JD, 2005]. GSTs are located 
in cytosol, mitochondria and microsomes; in some mammalian organs, they represent 
as much as 10% of the cytosolic protein [Boyer TD, 1989]. They comprise a large, 
functionally diverse family of enzymes, assigned in humans to 6 distinct classes: alpha, 
mu, theta, pi, zeta and omega (GSTA, GSTM, GSTT, GSTP, GSTZ and GSTO) GSTs carry 
out a wide range of functions in cells. They catalyses the conjugation of reduced 
glutathione (GSH) to electrophilic centers on a wide range of substrates. The 
conjugation between environmental pollutants and oxidized biomolecules to GSH, 
catalyzed by GSTs, is the major detoxification pathway in humans. GSTs also remove 
reactive oxygen species also formed by ionizing radiation exposure as confirmed by the 
activation of GST enzymes in response to radiation therapy [Helland A, 2007]. GSTs 
have also been shown to have a non-enzymic role. GSTs of the A, P and M classes 
modulate signalling pathways that control cell proliferation, cell differentiation and so 
on [Laborde E, 2010]. The genes encoding some GST enzyme loci are too polymorphic 
in humans; several polymorphisms in the GSTs may alter protein expression and/or 
function and can modify the risk in individuals exposed to toxic substrates (such as 
polycyclic aromatic hydrocarbons from smoke) or environmental pollutants [Manfredi 
S, 2007]. Deletion polymorphisms in the GSTM1 and GSTT1 genes, important members 
of the GST family, may result in complete function lack of GSTM1 and GSTT1 proteins 
[Pemble S, 1994]. During last year many studies have shown the association between 
DNA repair pathway and GST polymorphisms, mostly for GSTM1 and GSTT1, and 
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increased radiosensitivity in breast cancer patients [Mangoni M, 2011]. Polymorphisms 
resulting in reduced or absent activity in the GSTs activity have been associate with 
reduced hazard of death and risk of recurrence following treatment for breast cancer 
[Ambrosone CB, 2001]. Moreover GSTM1 and GSTT1 polymorphism may be significant 
in determining the level of adverse effects after radiotherapy. Variations in the level, 
activity, and ability to induce antioxidant enzymes may therefore be an indicator of 
radiosensitivity [Edvardsen H, 2007].  
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4. Aim of the thesis 
 
Ionizing procedures provide essential life-saving information, but great care must be 
taken regarding the possible long-term health consequences. The biological and 
clinical burdens of medical radiation represents a worrisome social and medical 
problem. 
Considerable efforts should be made to mitigate radiation-induced cell damage. 
Because radiation induced cellular damage is attributed primarily to the harmful 
effects of free radicals, the efficacy of non-toxic radioprotectors with radical 
scavenging properties should be investigated in the clinical setting. These agents may 
inhibit or reduce free radical toxicity, thus offering protection against radiation. 
The identification and characterization of genes that enhance prediction of disease risk 
and improve prevention, treatment, and quality of care remain important goals in the 
modern imaging practice. Specifically, it is anticipated that through the use of genetic 
markers may serve as the basis for personalized radiotherapy in which cancer 
management is formulated so that it optimizes the treatment plan for each patient 
based on their genetic background (radiogenomics). In order to improve this 
knowledge, the primary aims of the project were: 
- Aim 1: to evaluate the ability of NAC in conferring protection against radiation 
induced chromosomal DNA damage. 
- Aim 2: to assess the value of functional polymorphisms of genes involved in DNA 
damage repair and oxidative stress response as predictive factors for the 
occurrence of acute skin reactions. 
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5. Methods 
 
5.1. Study populations 
 
To evaluate the ability of NAC in conferring protection against radiation induced 
chromosomal DNA damage, we studied a population of 65 patients (52 males, age 64.4 
±11.9 years) who underwent to invasive cardiovascular procedures, including 
peripheral trans-luminal angioplasty (PTA; n =45), cardiac resynchronization therapy 
(CRT; n =15) and ablation therapy (AT; n =5). Exclusion criteria included the inability to 
obtain consent for participation in the study and the presence of acute or chronic 
inflammatory disease, immunological disease, and neoplastic disease. Eligible patients 
were classified into two groups: 35 patients (26 males, age 63.4±11.1 years) receiving 
the standard hydration protocol consisting of intravenous isotonic saline for 12 h after 
catheterization (Group I) and 30 patients (26 males, age 65.5±12.9 years) at risk for 
radiocontrast nephropathy with preexisting renal insufficiency (Group II). Group II 
patients received a double intravenous dose of NAC (6 mg/kg/h diluted in 250 mL of 
NaCl 0.9%) for 1 hour before and a standard dose (6 mg/kg/h diluted in 500 mL of NaCl 
0.9%) for 12 hours following catheterization.  
The X-ray equipments used in this study were Philips Integris H5000C Monoplane and 
Integris Allura Monoplane with the X- ray tube for both Systems: MRC 200 0508 ROT 
GS 1001. The DAP (Gy cm2) has been used for the estimation of the radiation dose 
received by the patient [Efstathopoulos EP, 2004; Kocinaj D, 2006] and is considered a 
valid indicator of a patient’s dose and consequent risk for radiation induced effects. 
Samples were collected from each subject and the laboratory analyses were 
performed in a random order.  
Conversely, to assess the value of functional polymorphisms of genes involved in DNA 
damage repair and oxidative stress response as predictive factors for the occurrence of 
acute skin reactions we studied female breast cancer patients receiving breast 
radiation therapy after conservative surgery (Stage I-III) at unit of Radiation Oncology 
of Brindisi Hospital “A. Perrino”. Fifty-nine patients were included in this prospective 
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single-arm study. The median age of patients was 58 years (range, 35-80 years). A 
detailed anamnestic history was collected from all patients, and blood sampling was 
performed for each of them, with written informed consent.  
All the patients received a typical breast-irradiation treatment. The planning target 
volume (PTV) dose prescription ranged from 40 Gy (54) and 50 Gy (2). All patients were 
given whole breast radiotherapy with conventional fractionation. Breast conserved 
patients received an additional boost (10 Gy) to the tumoral bed in 48/59 cases. 
Conventional fractionations (200 cGy/day) were used. Clinical radiation skin reaction 
within the radiation field of the breast was documented during the course of 
treatment and at the end of RT. The skin tissue reactions were graded according to the 
Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria 
[Cox J, 1995]. Skin tissue reactions after treatment for the 60 patients studied are 
shown in Table 3. Early acute toxicity (grade>1) was the end-point analyzed and was 
defined as early when occurred within few days after radiotherapy.  
 
 
Table 3. Acute skin tissue reaction at the end of radiotherapy course 
Acute skin toxicity, RTOG grade 
• Grade 0 No change       
• Grade 1 Follicular, faint or dull erythema, epilation, 
dry desquamation  
• Grade 2 Moderate erythema      
• Grade 3 Several desquamation     
• Grade 4 Ulceration, hemorrhage, necrosis    
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5.2 Cytokinesis-block micronucleus test 
 
Blood samples were collected at baseline, 2 hours following the procedure and 24 
hours after end of the catheterization procedures for MN assay as previously described 
[15-17]. Briefly, two separate cultures from each sample were set up by mixing 0.3 mL 
of whole blood with 4.7 RPMI 1640 medium: the cultures were incubated at 37°C for 
72 hrs. Cytochalasin B (6 µg/ml) was added 44 h after culture initiation. Cells were then 
harvested and fixed according to the standard methods. For each sample, 1000 
binucleated cells were scored under optical microscope (final magnification 400x) for 
micronucleus analysis, following the criteria for micronucleus acceptance. We 
evaluated the MN frequency as the number of micronucleated cells per 1000 cells (‰). 
For each sample, 1000 binucleated cells were scored under optical microscope (final 
magnification 400x) for micronucleus analysis, following the criteria for micronucleus 
acceptance. We evaluated the MN frequency as the number of micronucleated cells 
per 1000 cells (‰). 
 
 
5.3 PCR-RFLP Genotyping Assays 
 
All subjects enrolled in the study provided a blood sample (  3̴ mL) collected using 
standard venipuncture techniques before the start of radiotherapy. Whole blood 
samples for DNA analyses were immediately frozen at -80°C until processing. 
Genomic DNA was extracted from peripheral blood leukocytes. Genetic 
polymorphisms were analyzed by PCR combined with restriction fragment length 
polymorphism (RFLP) [Ambrosone CB, 2006; Veronesi U, 2001; Cancer Therapy 
Evaluation Program, 1998; Brenneman MA, 2000]. The primer pairs used were: (a) 
XRCC3: Thr241Met, F5′-GGTCGAGTGACAGTCCAAAC-3′ and R5′-
TGCAACGGCTGAGGGTCTT-3′ (b) XRCC1: Arg399Gln, F5′-AGTAGTCTGCTGGCTCTGG-3′ 
and R5′-TCTCCCTTGGTCTCCAACCT-3′ (c) XRCC1: Arg194Trp, F5′-GCCCCGTCCCAGTA-3′ 
and R5′-AGCCCCAAGACCCTTTCACT-3′ 
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Genomic DNA was isolated from cells in the venous blood using QIAmp kit (QIAmp 
DNA blood Mini Kit, Qiagen), following the manufacturer’s instructions, and the DNA 
quality was evaluated by the spectrophotometer analysis (NanoDrop, Thermo 
Scientific instrument). Details of annealing temperature, restriction enzymes and 
fragment sizes (pb) used to assess XRCC3 (Thr241Met), XRCC1 (Arg399Gln) and XRCC1 
(Arg194Trp) genetic polymorphisms are listed in Table 4.  
Genotyping of GSTM1 and GSTT1 deletions was carried out using a duplex PCR (in a 
volume of 50 µl) with the Albumin gene (ALB) serving as an internal positive control to 
prove the successful PCR amplification [Chen CL, 1997; Naveen AT, 2004]. In Table 4 
details of annealing temperature and fragment size. 
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Table 4. Condition for amplification, restriction enzyme and restriction patterns 
Primers 
Annealing 
Temperature 
(°C) 
Restriction 
Enzyme 
Fragment Sizes (pb) 
XRCC3 (Thr241Met) 
Forward primer 
GGTCGAGTGACAGTCCAAAC 
Reverse primer 
TGCAACGGCTGAGGGTCTT 
 
 
60 
 
 
Nla III 
315+140 (Thr/Thr) 
210+140+105 (Met/Met) 
XRCC1 (Arg399Gln) 
Forward primer 
GTTGGGCTCAAATATACGGTGG 
Reverse primer 
TCTCCCTTGGTCTCCAACCT 
56 MspI 
269 + 133 (Arg/Arg) 
402 (Gln/Gln) 
XRCC1 (Arg194Trp) 
Forward primer 
GCCCCGTCCCAGTA 
Reverse primer 
AGCCCCAAGACCCTTTCACT 
58 Pvu II 
490 (Arg/Arg) 
294 + 196 (Trp/Trp) 
GSTM1 
Forward primer 
GCCCCGTCCCAGTA 
Reverse primer 
GAACTCCCTGAAAAGCTAAAGC 
64  215 
GSTT1 
Forward primer 
TTCCTTACTGGTCCTCACATCTC 
Reverse primer 
TCACCGGATCATGGCCAGCA 
64  480 
ALB 
Forward primer 
GCCCTCTGCTAACAAGTCCTAC 
Reverse primer 
GCCCTAAAAAGAAAATCGCCAATC 
64  380 
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5.4 Statistical analysis 
 
Statistical analyses of the data were conducted with the Stat view statistical package, 
version 5.0.1 [Abacus Concepts, Berkeley, CA, USA]. Data are expressed as mean (+ 
SD). The sample size was projected to be 60 patients, with 30 to the treatment group 
and 30 to the control group, based on an increase of MN of 15%, a two-tailed alpha of 
0.05, and a power of 0.80. Qualitative and quantitative comparisons in demographic 
characteristics between Groups I and II were evaluated by χ2 analysis and the 
Student's t-test, respectively. Statistical differences in MN data between the two 
paired samples were determined with the non parametric Wilcoxon matched pairs 
test. Variations of MN with time in either group were assessed by using repeated-
measures analysis of variance (ANOVA). Comparisons among groups at each time point 
were made by means of the Kruskal–Wallis. A two-tailed p-value < 0.05 was chosen as 
the level of significance. In the logistic regression analysis, the homozygote of the most 
frequent allele was used as a reference. For odds ratio and 95% confidence interval, 
logistic regression analysis was used. The values of p-value < 0.05 were considered 
statistically significant.  
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6. Results  
 
6.1 NAC reduces chromosomal DNA damage  
 
The Clinical and demographic characteristics of study population are summarized in 
Table 5. Two groups were similar at baseline on demographic and clinical 
characteristics, including smoking status, dyslipidemia, hypertension, and diabetes 
mellitus. In particular, prior to the catheterization procedures there was no significant 
difference between frequencies (p=0.5).  
 
 
 
Table 5. Clinical and demographic characteristics of study patients 
Group        I° (n=35)  II ° (n=30)  p-value 
Mean age (±SD)     63.4±11.1  65.6±12.9  0.5  
Male sex, n (%)      26 (74.3)   26 (86.7)  0.2  
Hypertension, n (%)      19 (54.3)   12 (40)   0.2  
Diabetes, n (%)      5 (15.6)   4 (14.8)   0.9  
Dyslipidemia, n (%)      14 (40)   13 (43.3)   0.8  
Smoking, n (%)           0.9  
Never smokers      11(31.4)   8 (26.7)  
Former smokers      18 (51.4)   16 (53.3)  
Smokers       6(17.2)   6 (20)  
Baseline MN frequency (%)    14.5±4.7   13.7±7.0   0.5  
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Median effective DAP values were found to be significantly higher (p = 0.0001) in NAC-
treated patients (median 126.2 Gy cm2 range 15.9–260 Gy cm2) as compared to 
control group median 58.2 Gy cm2 range 7.5–114 Gy cm2), as shown in Fig 5. 
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Figure 5. DAP values for Group I (controls) and Group II (NAC+). 
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Figure 6. Frequency of MN at baseline, 2 and 24 h after cardiac catheterization 
procedures in the a) control patients (Group I) and b) NAC-treated patients (Group II). 
The results are expressed as boxes with 5 horizontal lines, displaying the 10th, 25th, 
50th 
 
MN frequency was 13.7 ± 4.7‰ at baseline and showed a significant rise at 2 h (18.0 ± 
6.8 p=0.01) and 24 h (17.6 ± 5.9, p=0.03) in the Group I (Fig 6). On the contrary, there 
was no significant increase of MN in the Group II (13.7 ± 7.0, 15.5 ± 6.0 and 14.9 ± 6.3 
for baseline, 2 h and 24 h respectively, p = 0.4).  
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Figure 7. MN levels at baseline, 2 h and 24 h after cardiac catheterization procedures 
 
A significant difference in MN frequency was also found between the treatment group 
and the control group at 24 h after procedures (Figure 7). We did not observe any 
relationship between DAP and % MN increase at 24 h for both Group I (r = 0.1, p=0.54) 
and Group II (r = 0.1, p=0.71). 
 
 
6.2 Association between genetic polymorphisms and acute skin 
toxicity in breast cancer  
 
The clinical and demographic characteristics of the whole set of breast cancer patients 
are shown in Table 6. Twenty-four (41%) of the 59 participants experienced faint to 
moderate acute skin toxicity (RTOG grade 1–2, grade ≥1) while 35 (59%) patients had 
no acute skin reactions (RTOG grade 0). A significant difference was recorded for the 
BMI value (p<0.01). Conversely, the two study population were similar for age, smoke 
status and RT treatment (boost therapy to the surgical bed).   
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Genotype distributions for XRCC3 Thr241 →Met  and XRCC1 Arg399 →Gln saasﬁed 
Hardy-Weinberg equilibrium. Conversely, the XRCC1 Asp194Trp  violated the 
equilibrium at the p < 0.05 level thus these polymorphisms were excluded from further 
analysis. The distributions of variants alleles in the whole set of breast cancer patients 
are shown in Table 5.  
 
Table 4. Clinical and demographic characteristics in the whole set of breast cancer 
patients (n = 59) after stratification according to skin toxicity criteria (Grade 0: no 
change; Grade ≥ 1: faint-moderate erythema) 
Clinical variable       Grade 0  Grade≥ 1             p-value 
         n = 35      n = 24 
Mean (SD) age, years   57     (11.6)  59.3 (11.7)     0.4 
BMI, mean (SD)   24.8 (4.3)  27.6 (4.7)     0.01 
Smoke, n (%)    4      (7)  3      (5)     0.9 
Tumor characteristics 
Histology, n (%) 
• Ductal-inasive (D)  24    (41)  15    (25) 
• Lobular-invasive (L)  3      (5)  3      (5) 
• Ductal in situ (DCIS)  2      (3)  2      (3) 
• Mixed (D + L)      2      (3) 
• Other    6      (10)  2      (3) 
Tumor stage, n (%) 
   I    21    (37)  13    (22) 
  IIA    6      (10)  3      (5) 
  IIB    1      (2)  3      (5) 
  III       1      (2) 
  IIIA    1      (2)  3      (5) 
  IIIB    3      (5)  1      (2) 
  IIIC    1      (2)  1      (2) 
Systemic therapy            0.6 
Hormonal therapy (H), n (%)  
• None, n (%)   6      (10)  5      (8) 
• Tamoxifen n (%)  14    (23)  5      (8) 
• Aromatase inhibitors n (%) 18    (32)  11    (18) 
Chemotherapy (C) n (%) 
• None, n (%)   12    (20)  12    (20) 
• Antracycline n (%)  11    (18)  7      (12) 
• Taxane n (%)   13    (23)  4      (6) 
Tumor bed boost therapy, n (%)         0.09 
• Yes    26    (74)  22   (92) 
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Table 5. Genotype and allele frequencies of Thr241 →Met polymorphism in XRCC3 
gene, Arg399 →Gln polymorphism in XRCC1 gene and GSTM1null and GSTT1null 
genotype in the study population 
      Grade 0 Grade ≥ 1          p-value 
      n = 35   n = 24 
|XRCC3| Thr
241 
→Met polymorphism      0.1 
      Thr/Thr, n (%)    21  (60) 9  (37.5) 
      Thr/Met, n (%)    11  (31.4) 9  (37.5) 
      Met/Met, n (%)    3    (8.6) 6  (25) 
TT vs TM + MM         0.08 
Allele 
      Thr, n (%)     53  (75.7) 27 (56) 
      Met, n (%)     17  (24.3) 21 (44) 
|XRCC1| Arg
399 
→Gln polymorphism      0.1 
      Arg/Arg, n (%)    22  (63) 11 (46)  
      Arg/Gln, n (%)    9    (26) 12 (50) 
      Gln/Gln, n (%)    4    (11) 1   (4) 
AA vs AG + GG         0.2 
Allele 
     Arg, n (%)     53  (76) 34 (71) 
     Gln, n (%)     17  (24) 10 (29)  
GSTM1
 
      Wild-type, n (%)    25  (71) 10 (42)  
      Null, n (%)     10  (29) 14 (59)   0.02 
GSTT1 
      Wild-type, n (%)    25  (71) 16 (67) 
      Null, n (%)     10  (29) 8   (33)   0.7 
 
At the univariate analysis the association between clinical variables and acute skin 
toxicity showed that a higher BMI (defined as BMI>24 kg/cm2) had a significant 
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adverse effects on acute skin toxicity. Patients with higher BMI have 3.6-fold risk to 
develop side reactions (CI: 1.2-11, p=0.02). Other factors evaluated, including age, 
smoking status and tumor bed boost therapy were not associated with an increased 
risk of acute skin toxicity. Regarding to patient genotype, subjects with Met/Met 
genotype in XRCC3 gene had a 2.5-fold increase risk of acute radiation skin toxicity as 
compared to patients with wild-type genotype (95% CI: 1.0-7.3, p=0.05) while the 
Arg399→Gln polymorphism in XRCC1 gene had no effect on acute skin toxicity. 
Similarly, the presence of GSTM1 null genotype increased almost 3-folds the risk of 
acute skin toxicity (OR: 3.5 CI: 1.2-10.4 p=0.02). No effect seemed to have the GSTT1 
null genotype in our population. ORs for genetic polymorphisms at univariate analysis 
are shown in Table 8.  
 
 
Table 6. Association between genetic polymorphisms and radiation-induced acute 
toxicity in breast cancer patients. 
      OR (95% CI)   p-value 
XRCC3 Thr
241
→Met 
   Thr/Thr     1.00 (ref) 
   Thr/Met + Met/Met   2.5 (1.0-7.3)   0.05 
XRCC1 Arg
399
→Gln 
   Arg/Arg     1.00 (ref) 
   Arg/Gln + Gln/Gln    2    (0.7-5.7)   0.2 
GSTM1
null 
   Wild-type     1.00 (ref) 
   Null      3.5 (1.2-10.4)   0.02 
GSTT1
null 
   Wild-type     1.00 (ref) 
   Null      1.2 (0.4-3.8)   0.7 
 
At logistic regression analysis, a BMI>24kg/cm2 was confirmed as an independent 
predictors of acute radiation-induced skin toxicity in breast cancer patients. Indeed, a 
higher BMI 3.6-fold increased the risk. Referring to genetic factors, also the Met/Met 
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genotype in XRCC3 gene and the GSTM1 null genotype were independent associated 
with the risk of acute breast skin toxicity following radiotherapy. The predictive 
efficiency of the logistic multivariate model according to the three independent 
predictors is summarized in the classification table reported in Table 9. 
 
 
Table 7. Predictive factors of acute skin toxicity by multivariate logistic regression 
analysis 
     OR (95% CI)    p-value 
XRCC3 Thr
241
→Met 
   Thr/Thr    1.00 (ref) 
   Thr/Met + Met/Met  3.12 (1.0 – 10.8)   0.05 
GSTM1
null 
   Wild-type    1.00 (ref) 
   Null     3.1 (1.0 – 10.0)   0.05 
BMI kg/cm
2
 
   BMI≤24 kg/cm2   1.00 (ref) 
   BMI>24 kg/cm2   4.5 (1.3 – 15.9)   0.02 
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7 Discussion 
The study proposal has been designed to evaluate the efficacy of NAC as new 
radioprotector in order to inhibit or reduce the free radical toxicity and, thus, offering 
protection against radiation during interventional cardiovascular procedures. In 
addition, the project assessed the role of genetic inter-individual differences in 
radiation-induced response.  
Regarding the efficacy of NAC treatment, this antioxidant resulted able to reduce 
radiation-induced chromosomal DNA damage in human lymphocytes after invasive 
cardiovascular procedures, possibly through its known action against free radicals.  
Indeed, it is known that invasive cardiovascular procedures can induce both DSBs (i.e. 
γ-H2AX) and chromosomal DNA damage [Geisel D, 2008; Bonassi S, 2008] largely by 
the generation of free radicals and ROS [Cadet J, 2012]. The ability to scavenge free 
radicals and reduce ROS is a critical function of radiation-protective agents [Weiss JF, 
2000]. 
The first in vivo studies on protection by chemicals against ionizing radiation were 
conducted almost 50 years ago. Patt et al., reported in 1949 that cysteine, a sulfur-
containing amino acid, could protect rat from a lethal dose of X-rays [Patt HM, 1949]. 
More than 4000 thiol-containing compounds have been screened in mice but the 
majority of these compounds are too toxic. Conversely NAC is a no  toxic, safe drug 
without major side-effects. It has been used in clinical setting for more than four 
decades [Miller LF, 1983; Kelly GS, 1998] and multiple clinically relevant effects have 
been described. Indeed, in addition to its direct ROS scavenging activity, NAC enhance 
the synthesis of GSH, and reduces inflammation [De Flora S, 2001]. NAC has been 
examined for its potential against radiation-induced injury, predominantly in vitro 
assays and, to some extent, in animals. NAC seems reduce ionizing radiation-induced 
DSB formation in human microvascular endothelial cells in vitro [Kataoka Y, 2007] and 
oxidative DNA damage in the liver of mice [Liu Y, 2007]. NAC treatment prior to 
radiation was found to decrease the lipid peroxidation, total nitrate/nitrite (NOx), DNA 
fragmentation and significantly increase the antioxidant status [Mansour H, 2008]. 
Finally, NAC showed protective effect against MN frequency in human blood 
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lymphocytes exposed in vitro to γ radiation [Tiwari P, 2009]. Our findings strongly 
support these evidences, suggesting the efficacy of NAC as radioprotector able to 
inhibit or reduce the free radical toxicity in human. 
This finding may have major clinical relevance since the use of radiation in medical 
diagnosis in western societies is increasing, especially for the growing use of computed 
tomography and interventional cardiology. In particular, in the United States, the dose 
from medical exposures has increased by a factor of six in the last 25 years [Mettler FA, 
2008]. 
The attributable cancer risk of getting cancer from medical radiation is estimated 
around 5 to 10% [Picano E, 2004], with approximately 29,000 future cancers (2% of all 
cancers) related to computed tomography scans in US [Berrington de González A, 
2009]. To date, in adult cardiology patients, interventional cardiology procedures 
account for roughly 12% of examinations, and 48% of the total collective dose [Bedetti 
G, 2008]. They contribute substantially to the high cumulative radiation doses of 
contemporary patients [Chen J, 2010]. 
The problem of medical ionizing radiation is more marked in children with congenital 
heart disease where the invasive radiology (with diagnostic and interventional 
catheterization) accounts for 6% of all radiological examinations and 84% of the 
collective dose [Ait Ali L, 2010]. With cumulative radiation exposure, the patient 
acquires increasing risks of developing cancer during their lifetime. 
As recommended in April 2010 by US President's Cancer Panel, any possible action 
should be taken by health care provides to minimize radiation exposure by medical 
sources, recognized as one of the 6 major causes of environmental cancer [President’s 
Cancer Pannel, 2010]. 
Dose optimization and is, therefore, of crucial importance for limiting radiation dose in 
cardiac catheterization procedures, especially for pediatric cardiac testing. For that, 
the use of specific radiation protector agents which acts as scavengers of reactive 
oxygen species is a crucial mean to reduce cell toxicity. NAC is a safe, inexpensive, and 
well-tolerated antioxidant with a well-defined mechanism of action [Millea PJ, 2009]. 
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The findings of this thesis support the notion that the use of NAC may be a promising 
approach in order to offer protection against DNA damage in patients undergone to 
interventional catheterization procedures. 
In the last years, many studies have provided a consistent evidence that several 
genetic, environmental and dietary factors can affect the variability of damage 
observed at any given level of radiation. In particular a major role of genetic 
polymorphism of genes involved in DNA damage and repair in modulating the 
vulnerability to radiation exposure in the very low dose range has been evidenced. 
Accordingly, the seventh National Academy of Science report on Biological Effects of 
Ionizing Radiation (BEIR VII) recommended the identification of genes conferring 
predisposition to radiation-induced health effects as a top research need. So that, the 
characterization of genes that enhance prediction of disease risk and improve 
prevention, treatment, and quality of care remain important goals. In particular, the 
use of genetic markers may serve as the basis for personalized radiotherapy in which 
cancer management is formulated to optimize the treatment plan for each patient 
based on their genetic background (radiogenomics). Skin reaction during radiotherapy, 
though reversible in the large majority of cases, is the most common side effect in 
breast cancer patients. Acute effects such as erythema (redness, warmth, rash-like 
appearance), dry desquamation (dryness, itching, peeling), or moist desquamation 
(moist, oozing, tender, redness and exposure of the dermis) occur during or shortly 
after therapy. However cancer patients exhibit large patient-to-patient variability in 
acute skin reactions when the same treatment regimen is applied. Several 
observations support the hypothesis that radiosensitivity of clinical normal tissue is 
influenced by several polymorphic genes in DNA repair mechanisms and also oxidative 
stress [Zhou L, 2010, Ambrosone CB, 2006]. Some genetic variants of XRCC1 and XRCC3 
genes have been shown to correlate with hypersensitivity to radiotherapy [Moullan N, 
2003]. In addition, Alsbeih G et al. have showed that XRCC3 Met241 variant influence 
radiosensitivity of human fibroblasts and that more risk allele of susceptible genes 
have a combined effect on cellular radiation response, suggesting that individuals with 
multiple risk alleles could be more predisposed to radiation effects than those with 
fewer risk alleles [Alsbeih G, 2007]. Recently, Mangoni M et al. showed the protective 
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role of XRCC3 wild type genotype towards acute skin side effects [Mangoni M, 2011]. 
In this study we confirm the association of XRCC3 Thr241→Met polymorphism as 
independent predictor of individual susceptibility to acute skin toxicity. Indeed, the 
presence of this polymorphism 3-fold  increased the risk  (95% CI 1.0 – 10.8; p<0.05).  
Similarly, the genetic background of detoxification enzyme may confer an individual 
susceptibility to ionizing radiation. Indeed, it is known that radiotherapy leads to the 
induction of antioxidant enzymes, such as glutathione S-transferases. The GSTs are 
important members of the cellular phase II detoxification system, and they catalyze 
the reactive oxygen species scavenging process by conjugation of the tripeptide 
glutathione to a variety of endogenous and exogenous electrophilic compounds. A lack 
of GSTM1 and GSTT1 enzyme activity is caused by homozygous deletion of the 
corresponding genes and is observed in 50% and 20% of the Caucasian population, 
respectively [Sharma A, 2012].  
In our study, the evaluation of the potential effects of null GST genotypes has showed 
that breast cancer patients carrying null GSTM1 genotype was associated with a more 
than three-fold increase in risk for experiencing acute skin toxicities (OR: 3.5 CI: 1.2-
10.4 p=0.02). This suggests that a reduced or absent activity in the GSTM1 enzyme may 
result in a greater risk of radiation-associated toxicity likely by influencing the cellular 
redox state. Thus, polymorphisms in genes associated with higher generation of ROS 
appear to increase susceptibility to development of normal tissue complications, 
whereas gene variants associated with lower ROS production may decrease risk of 
these effects [Chang-Claude J, 2009]. The identification of risk factors, related to 
radiation therapy, among clinical characteristics and genetic background of cancer 
patients are important feature to predict the probability of undesirable effects and 
also to allow optimization of radiotherapy treatment. The genetic polymorphisms 
evaluated may be promising candidates for predicting acute radiosensitivity, but 
further studies will need to be carefully confirm these results in largest population.  
Moreover, our results also showed that a higher BMI increased the risk of early acute 
skin reaction. The finding of BMI as a risk factor is compatible with previous 
observations which underline breast size as an important prognostic factor for acute 
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toxicity since BMI and breast size are likely to be highly correlated [Gray JR, 1991]. A 
greater dose in-homogeneity across the breast and a greater field separation in 
patients with larger breasts could be reasons for this association.  
 
8. Conclusions 
In conclusions, the results reported in this thesis provide evidence that: 
 
- NAC may be an effective promising, safe, inexpensive, and well-tolerated antioxidant 
approach easily usable in the clinical practice to offer protection against DNA damage 
induced by ionizing radiation exposure during cardiac catheterization procedures. This 
observation may have potential application in clinic practice in order to improve the 
protection of the patients from the adverse health effects of ionizing radiation, 
especially for pediatric patients.  
 
- SNPs in DNA repair and detoxification genes can modify the susceptibility to inter-
individual differences in response to therapeutic ionizing radiation exposure in breast 
cancer patients following radiation therapy. The association analysis between clinical 
characteristics and genotype with the acute radiation skin toxicity in breast cancer 
patients suggests that approaches based on (multiple) genetic markers and clinical 
characteristics have the potential to predict normal tissue radiosensitivity.  
Although our findings are to be carefully assessed with further large, randomized 
studies, taken together have outmost clinical relevance since add important 
information to provide new insights to reach a personalized measure of radiation risk. 
All this in order to implement tailored preventive and chemopreventive strategies. 
Indeed, in the era where the use of ionizing radiation is exponentially increasing,  a 
parallel advance in the knowledge of new strategy to protect cellular DNA damage as 
well as in the knowledge of individual susceptibility is strongly need for a better 
therapeutic program able to improve the life quality of patients.  
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